End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5,69,960 COP | -.--% | -2.50% | -6.36% |
31/05 | Sector Update: Health Care Stocks Higher Late Afternoon | MT |
31/05 | US lawmakers ask FBI for briefing on GenScript Biotech's links to China | RE |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- With an enterprise value anticipated at 3.93 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.36% | 350B | - | ||
+40.73% | 734B | C+ | ||
+32.83% | 591B | B | ||
+15.15% | 315B | B- | ||
+4.05% | 276B | C+ | ||
+15.00% | 238B | B+ | ||
+9.78% | 206B | B- | ||
-5.52% | 204B | A+ | ||
+6.17% | 161B | C+ | ||
-0.45% | 160B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JNJ Stock
- JNJ Stock
- Ratings Johnson & Johnson